Scion NeuroStim
14
1
1
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
57.1%
8 terminated/withdrawn out of 14 trials
38.5%
-48.0% vs industry average
0%
0 trials in Phase 3/4
140%
7 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
STEM-PD Open Label Extension (OLE)
Role: lead
Examining the Effects of Neuromodulation on Glucose Metabolism in Type 2 Diabetes
Role: lead
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache
Role: lead
STEM-Parkinson's Disease
Role: lead
SHARPEN - Parkinson's Disease Dementia
Role: lead
A Pilot Study of a Non-Invasive Neuromodulation Device for Treatment of Parkinson's Disease
Role: lead
Neurostimulation Device for Treatment of Migraine Headache
Role: lead
Effects of Neuromodulation on Verbal Fluency in Post-stroke Aphasia
Role: lead
The Effects of Non-invasive Neuromodulation on Illness Awareness in Schizophrenia
Role: collaborator
Neuromodulation for Schizophrenia
Role: lead
WeArable Neuromodulation DeVice for the TrEatment of Alzheimer's Disease
Role: lead
A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache
Role: lead
Neuromodulation Treatment of Vestibular Migraines
Role: collaborator
Caloric Stimulation on Cerebral Blood Flow
Role: collaborator
All 14 trials loaded